Evidence map›Paper›PMID 25868510›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2015

The position of strontium ranelate in today's management of osteoporosis.

J-Y Reginster, M-L Brandi, J Cannata-Andía, C Cooper, B Cortet, J-M Feron, H Genant, S Palacios, J D Ringe, R Rizzoli

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. In vivo quantification of strontium in bone among adults using portable x-ray fluorescence.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Review
  17. Article
  18. Article
  19. Review
  20. The Bromodomain InhibitorInternational journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 8 countries.

J-Y ReginsterDepartment of Public Health, Epidemiology and Health Economics, University of Liège, 4020, Liège, Belgium. jyreginster@ulg.ac.be.
M-L BrandiMetabolic Bone Unit, Department of Internal Medicine, University of Florence, Florence, Italy.
J Cannata-AndíaServicio de Metabolismo Óseo y Mineral, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain.
C CooperMRC Lifecourse Epidemiology Unit and NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK.
B CortetService de Rhumatologie, Hôpital Roger Salengro, Lille, France.
J-M FeronService de Chirurgie Orthopédique et Traumatologique, Hôpital Saint Antoine, UPMC, Paris, France.
H GenantDepartments of Radiology, Medicine, Epidemiology and Orthopedic Surgery, University of California, San Francisco, CA, USA.
S PalaciosInstituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain.
J D RingeMed Klinik 4, Klinikum Leverkusen, Akadem, Lehrkrankenhaus, University of Cologne, Cologne, Germany.
R RizzoliDivision of Bone Diseases, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland.
Hôpital Roger Salengro · FRHôpital Saint-Antoine · FRInstituto Palacios · ESKlinikum Leverkusen · DEMRC Lifecourse Epidemiology Unit · GBUniversidad de Oviedo · ESUniversity Hospital of Geneva · CHUniversity of California, San Francisco · USUniversity of Florence · ITUniversity of Liège · BE

Funding

Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1
6 · The paper itself

Abstract

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving, especially in patient with severe osteoporosis or patients who cannot take certain osteoporosis medications due to issues of contraindications or tolerability. Following recent regulatory changes, strontium ranelate is now indicated in patients with severe osteoporosis for whom treatment with other osteoporosis treatments is not possible, and without contraindications including uncontrolled hypertension, established, current or past history of ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. We review here today's evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy of strontium ranelate is maintained in patients with severe osteoporosis without contraindications and also demonstrated how the new target population mitigates risk. Strontium ranelate is therefore an important alternative in today's management of osteoporosis, with a positive benefit-risk balance, provided that the revised indication and contraindications are followed and cardiovascular risk is monitored. The bone community should be reassured that there remain viable alternatives in patients in whom treatment with other agents is not possible and protection against the debilitating effects of fracture is still feasible in patients with severe osteoporosis.

Indexed as

Bone Density Conservation AgentsDrug ApprovalDrug PrescriptionsHumansOsteoporosisRisk AssessmentThiophenesTreatment OutcomeBone Density Conservation Agentsstrontium ranelateThiophenesEfficacyOsteoporosisSafetyStrontium ranelateTreatment

Identifiers

PMID25868510
OpenAlexW2054213732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.